
OpenPrivate placementGoodsomnia AB
Goodsomnia has developed a handheld device that reduces snoring by strengthening the muscles of the soft palate – two minutes a day for three weeks, with nothing to wear at night. Patented in nine markets.
About the company
Around 2 billion people worldwide snore, by the company's estimate. Among people over 40, about 44 percent of men and 28 percent of women snore. The products available today are worn at night and dampen the symptoms, but do nothing about the cause.
Goodsomnia's device is a handheld muscle stimulator the size of an electric toothbrush. Using patented biomechanical muscle stimulation (BMMS), it strengthens the muscles of the soft palate, which otherwise vibrate and cause snoring. It is used for two minutes a day for about three weeks, and nothing has to be worn at night. It comes with the Goodsomnia Lab app, which records and analyses snoring with AI.
The technology builds on Professor Nazarov's research into mechanical muscle stimulation. In a clinical validation at an ear, nose and throat clinic in Kharkiv, led by Professor Grygoriy Garyuk, snoring fell by 50–65 percent after 21 days. The study had 14 participants. Patents are granted in Sweden, the EU, the USA, China, Japan, South Korea, Australia, Canada and India.
The company will first sell directly to consumers online and then through pharmacy chains, clinics and resellers. Manufacturing is done by suppliers. The device is expected to bring about 65 percent of revenue and accessories and sensors the rest, and the app has a premium version with a subscription. In the company's plan, break-even comes at about 10,000 units sold.
The issue pays for production tooling, the first series and the launch. The founders Hans-Jörgen Henriksson and Robert Åslund have together invested about SEK 4.7m in the company and, ahead of the issue, converted their loans of SEK 1.1m into shares at the same price, SEK 120. In time the company intends to list on a Swedish marketplace, once sales are under way and it has at least 300 shareholders.
At a glance
Highlights
- 50–65% less snoring after 21 days of 2 minutes a day, according to the doctors who led the company's validation study at an ear, nose and throat clinic in Kharkiv (14 participants). In the first two participants, measured by polysomnography, snoring fell by 62% and 63%
- Patents granted in nine major markets: Sweden, the EU, the USA, China, Japan, South Korea, Australia, Canada and India
- Seal of Excellence from the European Commission in 2019, followed by SEK 500,000 from Vinnova
- Selected among Europe's top digital health companies from 3,000 applicants to StartupBootCamp in Berlin in 2018
- Google has offered the company cloud credits worth USD 350,000
Key facts
- Founded
- 2,016
- Registered office
- Stockholm, Sweden
- Employees
- 5
- Granted patents
- 9 major markets
- Validation study participants
- 14
- App downloads (Android)
- 17,000
- Founders' investment
- about SEK 4.7m
- Global snoring market
- over USD 20bn a year
- Estimated people who snore worldwide
- 2 billion
How the Goodsomnia Lab app works
The film loads from YouTube when you press play.
Team & board
The people who run the company and their roles.
Hans-Jörgen HenrikssonStyrelseordförande och vdGrundare och meduppfinnare av Goodsomnias teknik. Över 30 års erfarenhet av produkt- och affärsutveckling inom IT, telekom och medtech; har grundat fler än 14 bolag och noterade ett IT- och telekombolag på en svensk handelsplats 1999/2000. Har arbetat utan lön i Goodsomnia sedan starten 2016.
Robert ÅslundStyrelseledamotBolagets första investerare och aktiv partner sedan 2016, teknikansvarig (CTO) och medförfattare till valideringsrapporten. Utbildad vid KTH, med 30 års erfarenhet av produktledning, marknadsföring och affärsutveckling i snabbväxande medtech- och bioteknikbolag i Sverige och USA.